Log In Get Started
Press Releases April 29, 2026 08:05 PM

Vaccinex Reports 2025 Annual Financial Results

Vaccinex Reports 2025 Annual Financial Results Highlighting Progress in Neurodegenerative Diseases and Cancer Therapeutics

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
VCNX

Vaccinex, Inc., a clinical-stage biotechnology company focused on developing novel antibody therapies for Alzheimer’s, Huntington’s disease, and cancer, released its financial results for 2025. The company is advancing its pipeline with plans to initiate a Phase 2b study in Alzheimer's disease, demonstrating ongoing commitment to addressing serious diseases with unmet medical needs.

Vaccinex Reports 2025 Annual Financial Results
VCNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Vaccinex is pioneering novel investigational antibody therapies targeting neurodegenerative diseases and cancer.
  • The company released its 2025 financial results, with details posted on its website.
  • Vaccinex is initiating a new Phase 2b clinical trial in Alzheimer’s disease, signaling pipeline progress.

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in Alzheimer’s disease. Vaccinex is based in Rochester, New York.

Investor Contact
Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 271-2700
[email protected]


Risks

  • As a clinical-stage biotech company, Vaccinex faces risks related to clinical trial outcomes and regulatory approvals.
  • Financial performance details, while released, were not highlighted, suggesting potential uncertainties in revenue and funding.
  • The biotechnology sector remains volatile, with investments dependent on successful product development and market acceptance.

More from Press Releases

Devon Energy Announces Agreement to Exit the Eagle Ford for $4.2 Billion Oct 8, 2026 Microchip Introduces its First Turnkey Touch Controllers for Buttons, Sliders and Wheels with Parallel Sensing Oct 8, 2026 Gilat Secures Over $8 Million in Additional Orders from the U.S. Department of War Oct 8, 2026 Auddia Posts CEO Letter to Shareholders Highlighting LT350 Momentum, Strategic Partnerships, and AI Infrastructure Opportunity Oct 8, 2026 Gogo signs a multi-million USD communications contract with overseas sovereign customer Oct 8, 2026